With $36bn from Teva, what should Allergan buy next?
This article was originally published in Scrip
Executive Summary
Allergan left all options on the table in terms of the types of deals that the ever-growing company will pursue with its $36bn in after-tax proceeds from the $40.5bn sale of its generics business to Teva Pharmaceutical Industries.